

ASSOCIATION OF TRANSCRIPTION FACTOR 7 LIKE 2 (TCF7L2) POLYMORPHISMS WITH DIABETIC RETINOPATHY

ABSTRACT

Diabetic retinopathy (DR) is a multifactorial disease which causes blindness among people worldwide. It has complex pathophysiology linked to various genetic variations. TCF7L2 (Transcription factor 7 like 2) is considered as one of the most important candidate genes which plays a major role in hyperglycemia and neovascularization. The purpose of this review is to highlight the role of TCF7L2 polymorphisms in the development of DR. We used available published data to explain the association of TCF7L2 polymorphisms with DR. We concluded that genetic studies reports revealed TCF7L2 polymorphisms might be associated with DR development.

Keywords DM, DR, NPDR, PDR, TCF7L2, wnt, polymorphism

1. INTRODUCTION

Diabetes mellitus (DM) is a metabolic disorder in which chronic hyperglycemia result to defect in insulin secretion or action leading to acute and chronic complications [1]. The complication usually manifest in the form of damage to vascular system of the body and are less common in DM patients with controlled hyperglycemia [2]. Uncontrolled hyperglycemia causes impaired metabolism which may result in oxidative stress, increased lipolysis (breakdown of lipids), elevated ketone bodies and increased gluconeogenesis [3, 4]. These factors affect the body tissues and subsequently they can cause both morphological and functional defects in organs such as the heart, kidneys, liver and eye [5]. Diabetic Retinopathy (DR) is a diabetic complication which causes morphological damage to the eye leading to visual impairment and blindness [6]. DR clinically leads to retinal ischemia accompanied by hemorrhages, destruction of the pericytes referred to as microaneurysms, hard exudates, cotton wool spots, intraretinal microvascular abnormalities and neovascularization [7–9]. The early stage of DR is characterized by vascular permeability; this condition is called non-proliferative diabetic retinopathy (NPDR) whereas progression of the NPDR results in abnormal growth of the retinal blood vessels leading to the neovascularization that is a major symptom in the advanced stage of DR, which is known as proliferative diabetic retinopathy (PDR) [10] (Fig. 1). Recent researches have shown abnormalities in the expression of glucagon like peptide-1 (GLP-1); an incretin hormone lead to hyperglycemia and vascular endothelial growth factor (VEGF), which subsequently lead to neovascularization that might be triggered as a result of variations in the gene of a transcription factor in the wnt signaling pathway referred to as transcription factor 7 like 2 (*TCF7L2*) [11–15].

2. TRANSCRIPTION FACTOR 7 LIKE 2 (TCF7L2)

Transcription factor 7 like 2 (*TCF7L2*) gene spans 17 exons on chromosome 10q25.3 which encodes for a transcription factor involved in the Wnt signaling pathway [16, 17] (Fig 2). Several single nucleotide polymorphisms (SNPs) including rs7903146 and rs12255372 in the intron region of the *TCF7L2* were identified and found to have association with metabolic disorders including T2DM. The rs7903146 is a nucleotide change from C to T at position 112998590 in the fourth intron of *TCF7L2*, whereas rs12255372 is a change in nucleotide at position 113049143 in the fifth intron from G to T (Fig 3).

Genome-wide association studies (GWAS) reported a relationship between a common micro-satellite region (DG10S478) in intron 3 of the *TCF7L2* gene and T2DM [7, 8]. In addition, several studies identified other polymorphisms of *TCF7L2* gene associated to T2DM, amongst which are rs7903146 (C/T) and rs12255372 (G/T) [20].





Figure 1 Fundus images of DR progression. This progression develops from background DR (mild DR) a form of NPDR to Fibrovascular membrane a form of PDR, as the DR progresses new vessels are formed. Gradual loss in the red colour and change in vein size occur with progression of DR [21].

A) Wnt ligand absent

B) Wnt ligand present

59



60

61

62 **Figure 2. Canonical Wnt signaling pathway A) Shows β catenin regulation in the absence of wnt**
 63 **ligands. The destruction complex containing CK 1 α , axin, APC, and GSK-3 phosphorylates β**
 64 **catenin and mark it for proteosomal degradation B) Shows the β catenin stimulation in presence**
 65 **of wnt ligands which prevents interaction between the destruction complex and β catenin and**
 66 **subsequently promote wnt targeted gene expression [12].**

67

68

69




Figure 3. *TCF7L2* gene structure. The *TCF7L2* is located in chromosome 10q25.3. The blue coloured bar-shape are exons whereas the green coloured bar-shape indicate exons that undergo alternative splicing, STOP is the region where transcription of *TCF7L2* gene terminate, whereas The two single nucleotide polymorphisms (SNPs) in red are the most studied [12].

3. ASSOCIATION OF DIABETIC RETINOPATHY TO *TCF7L2*

Genetic variation of rs7903146 (c.382-41435C>T) and rs12255372 (c.482+9017G>T) were successfully linked to T2DM in various ethnic groups [1, 13, 18, 20, 22–25]. But it is still not clear if *TCF7L2* genetic variant is related to DR [26, 27].

Although the exact role of *TCF7L2* in DR is not clearly established. However, polymorphisms in the *TCF7L2* might be associated with DR via Wnt targeted genes, several studies have reported the association of these genes with DR in different cohorts i.e. Chinese, Japanese, Indian and American population VEGF [15, 28, 29], ICAM-1 [30, 31] and eNOS [28, 32]. Investigation on PDR shows the relationship between *TCF7L2* and *VEGFα* [27]. The expression of *VEGFα* increases with increase in expression of *TCF7L2*. Therefore, the genetic polymorphism condition is associated with elevated *TCF7L2* levels which implicates in over expression of *VEGFα*; related to derangement of retinal vessels and neovascularization [27]. We believe the mechanism revealing the association of *TCF7L2* polymorphism to *VEGFα* is applicable to other genes expressed by *TCF7L2* in the wnt signaling pathway.

CONCLUSION

In addition to confirming the association of *TCF7L2* gene variants to DM, *TCF7L2* SNPs might play a role in the development of DM complications including DR.

REFERENCES

1. Dalhat MH, Bashiru I, Bello HJ, Saidu Y, and Abbas AY. Association of Transcription Factor 7 Like 2 (*TCF7L2*) rs12255372 (G/T) Gene Polymorphism and Type 2 Diabetes Mellitus," *Journal of*

- 95 *Advances in Biology & Biotechnology*. 2017. 15 (4); 1–7.
- 96 2. Maji D. Prevention of microvascular and macrovascular complications in diabetes mellitus,”
97 *Journal of the Indian Medical Association*. 2004. 102(8): 426–436.
- 98 3. Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy
99 setting. *Physical therapy*. 2008. 88 (11);1322–35.
- 100 4. Cunha-Vaz JG. Pathophysiology of diabetic retinopathy. *The British journal of ophthalmology*.
101 1978. 62(6);351–5.
- 102 5. Fowler MJ. Microvascular and Macrovascular Complications of Diabetes, *Clinical Diabetes*. 2008.
103 26(2);77–82.
- 104 6. Kowluru RA, Zhong Q, Santos JM, Thandampallayam M, Putt D, Gierhart DL. Beneficial effects of
105 the nutritional supplements on the development of diabetic retinopathy. *Nutrition & metabolism*.
106 2014.11(1);8.
- 107 7. Alami FM, Ahmadi M, Bazrafshan H, Tabarraei A, Khosravi A, Tabatabaiefar MA, Samaei NM.
108 Association of the TCF7L2 rs12255372 (G/T) variant with type 2 diabetes mellitus in an Iranian
109 population. *Genetics and Molecular Biology*. 2012. 35(2); 413–417.
- 110 8. Ola MS. *Edited by Mohammad Shamsul Ola*. Croatia: aneza Trdine 9, 51000 Rijeka, Croatia.
111 2012.
- 112 9. Kowluru RA, Zhong Q, Santos JM. Matrix metalloproteinases in diabetic retinopathy: potential role
113 of MMP-9., *Expert opinion on investigational drugs*.2012. 21(6);797–805.
- 114 10. Alghadyan AA. Diabetic retinopathy – An update, *Saudi Journal of Ophthalmology*.2011. 25(2);
115 99–111.
- 116 11.. Freeman JS, “Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus,”
117 *Cleveland Clinic Journal of Medicine*. 2009; 76(5):12–19.
- 118 12. Chiang Y-TA., Ip W, Jin T. The role of the Wnt signaling pathway in incretin hormone production
119 and function. *Frontiers in physiology*. 2012;(3): 273.
- 120 13. Ciccacci C, Di Fusco D, Cacciotti L, Morganti R, D’Amato C, Novelli G, Sangiuolo F, Spallone V,
121 Borgiani P. TCF7L2 gene polymorphisms and type 2 diabetes: Association with diabetic
122 retinopathy and cardiovascular autonomic neuropathy. *Acta Diabetologica*. 2013;5(50): 789–799.
- 123 14. Migliorini A, Lickert H. Beyond association: A functional role for Tcf7l2 in β -cell development.
124 *Molecular metabolism*. 2015;5(4):365–366.
- 125 15. Lyssenko V, Lupi R, Marchetti P, Del Guerra S, Orho-Melander M, Almgren P, Sjögren M, Ling C,
126 Eriksson KF, Lethagen AL, Mancarella R, Berglund G, Tuomi T, Nilsson P, Del Prato S, Groop L.
127 Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes. *The*
128 *Journal of clinical investigation*. 2007; 117(8):2155–2163.
- 129 16. Groop L. Open chromatin and diabetes risk. *Nature Publishing Group*. 2010; 10(3):190–192.

- 130
- 131 17. Buraczynska M, Zukowski P, Ksiazek P, Kuczmazewska A, Janicka J, Zaluska W. Transcription
132 factor 7-like 2 (TCF7L2) gene polymorphism and clinical phenotype in end-stage renal disease
133 patients. *Molecular Biology Reports*. 2014;6(41):4063–4068.
- 134 18. Grant SFA, Thorleifsson G, Reynisdottir I, Benediktsson R, Manolescu A, Sainz J, Helgason A,
135 Stefansson H, Emilsson V, Helgadóttir A, Styrkarsdóttir U, Magnusson KP, Walters GB, Palsdóttir
136 E, Jonsdóttir T, Gudmundsdóttir T, Gylfason A, Saemundsdóttir J, Wilensky RL, Reilly MP, Rader
137 DJ, Bagger Y, Christiansen C, Gudnason V, Sigurdsson G, Thorsteinsdóttir U, Gulcher JR, Kong
138 A, Stefansson K. Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2
139 diabetes. *Nature genetics*. 2006; 38(3):320–323.
- 140 19. Buraczynska M, Swatowski A, Markowska-Gosik D, Kuczmazewska A, Ksiazek A. Transcription
141 factor 7-like 2 (TCF7L2) gene polymorphism and complication/comorbidity profile in type 2
142 diabetes patients. *Diabetes research and clinical practice*. 2011;3(93):390–395.
- 143 20. Nanfa D, Sobngwi E, Atogho-Tiedeu B, Noubiap JJN, Donfack OS, Mofo EPM, Guewo-Fokeng M,
144 Nguimmo Metsadjio A, Ndonwi Ngwa E, Pokam Fosso P, Djahmeni E, Djokam-Dadjeu R, Evehe
145 MS, Aminkeng F, Mbacham WF, Mbanya JC. Association between the TCF7L2 rs12255372 (G/T)
146 gene polymorphism and type 2 diabetes mellitus in a Cameroonian population: a pilot study.
147 *Clinical and translational medicine*. 2015;(4):17.
- 148 21. Wu G. *Diabetic Retinopathy: The Essentials*. Lippincott Williams & Wilkins.2012.
- 149 22. Dalhat MH, Bello HJ, brahim B, and Labbo A. Association of rs7903146 TCF7L2 (C/T) Gene
150 Polymorphism and Type 2 Diabetes Mellitus in Pakistani Population. *Journal of Applied Life*
151 *Sciences International*. 2017. 14(4):1–7.
- 152 23. Ip W, Chiang Y, Jin T. The involvement of the wnt signaling pathway and TCF7L2 in diabetes
153 mellitus: The current understanding, dispute, and perspective, *Cell & Bioscience*.2012. 2(1);28.
- 154 24. Bodhini D, Radha V, Dhar M, Narayani N, Mohan V. The rs12255372(G/T) and rs7903146(C/T)
155 polymorphisms of the TCF7L2 gene are associated with type 2 diabetes mellitus in Asian Indians.
156 *Metabolism: clinical and experimental*. 2007; 56(9):1174–1178.
- 157 25. Javadi MA, Katibeh M, Rafati N, Dehghan MH, Zayeri F, Yaseri M, Sehat M, Ahmadi H.
158 Prevalence of diabetic retinopathy in Tehran province: a population-based study. *BMC*
159 *ophthalmology*. 2009.9;12.
- 160 26. Sudchada P, Scarpac K. Diabetic Retinopathy : a Systematic Review,” *Genetics and Molecular*
161 *Research*.2014.13(3);5865–5872.
- 162 27 Luo J, Zhao L, Chen AY, Zhang X, Zhu J, Zhao J, Ouyang H, Luo H, Song Y, Lee J, Patel SH,
163 Shaw PX, Sadda S, Zhuo Y, Rosenfeld MG, Zhang K. TCF7L2 Variation and Proliferative Diabetic
164 Retinopathy. *Diabetes*. 2013;7(62):2613–2617.

28. Suganthalakshmi B, Anand R, R. Kim, R. Mahalakshmi, Karthikprakash S, Namperumalsamy P, Sundaresan P. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. *Molecular vision*. 2006. 12:336–341.
29. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K, Inoue I, Katayama S. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. *Diabetes*. 2002; 51(5):1635–1639.
30. Sun H, Cong X, Sun R, Wang C, Wang X, Liu Y. Association between the ICAM-1 K469E polymorphism and diabetic retinopathy in Type 2 diabetes mellitus: A meta-analysis, 2014.
31. Vinita K, Sripriya S, Prathiba K, Vaitheeswaran K, Sathyabaarathi R, Rajesh M, Amali J, Umashankar V, Kumaramanickavel G, Pal SS, Raman R, Sharma T, SNDREAMS project. ICAM-1 K469E polymorphism is a genetic determinant for the clinical risk factors of T2D subjects with retinopathy in Indians: a population-based case-control study. *BMJ open*.2012.2(4);e001036.
32. Verma QUA, Han P.-Y., Nakagawa T, Johnson RJ, Grant MB, Campbell-Thompson M, Jarajapu YPR, Lei B, Hauswirth WW. Diabetic eNOS-knockout mice develop accelerated retinopathy.,” *Investigative ophthalmology & visual science*.2010.51(10);5240–6.